![Christy Marshuetz Ferguson](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Christy Marshuetz Ferguson
No más puestos en curso
Perfil
Christy Marshuetz Ferguson worked as a Vice President of Business Development at GeneCentric Therapeutics, Inc. She received an undergraduate degree from the University of Michigan, a doctorate degree from the University of Michigan in 2000, and an MBA from Kenan-Flagler Business School in 2008.
Antiguos cargos conocidos de Christy Marshuetz Ferguson.
Empresas | Cargo | Fin |
---|---|---|
GeneCentric Therapeutics, Inc.
![]() GeneCentric Therapeutics, Inc. Medical SpecialtiesHealth Technology GeneCentric Therapeutics, Inc. develops and commercializes molecular diagnostic assays. Its product enables oncologists and patients to make more informed, individualized treatment decisions. The firm's product CSP identifies cancer subtypes that enable drug developers to meet the growing demand for precision medicines, and provide clinicians the information they need to make individualized treatment decisions. The company was founded by David Neil Hayes, Charles M. Perou, and Myla P. Lai-Goldman in 2011 and is headquartered in Durham, NC. | Corporate Officer/Principal | - |
Formación de Christy Marshuetz Ferguson.
University of Michigan | Undergraduate Degree |
Kenan-Flagler Business School | Masters Business Admin |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas privadas | 1 |
---|---|
GeneCentric Therapeutics, Inc.
![]() GeneCentric Therapeutics, Inc. Medical SpecialtiesHealth Technology GeneCentric Therapeutics, Inc. develops and commercializes molecular diagnostic assays. Its product enables oncologists and patients to make more informed, individualized treatment decisions. The firm's product CSP identifies cancer subtypes that enable drug developers to meet the growing demand for precision medicines, and provide clinicians the information they need to make individualized treatment decisions. The company was founded by David Neil Hayes, Charles M. Perou, and Myla P. Lai-Goldman in 2011 and is headquartered in Durham, NC. | Health Technology |
- Bolsa de valores
- Insiders
- Christy Marshuetz Ferguson